As you will be aware, the Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of pembrolizumab for previously treated triple-negative breast cancer.
However, following on from information received from the company regarding the recent results of the KEYNOTE-119 clinical trial to support this indication and that they did not meet the pre-specified primary endpoint, NICE has decided to suspend this appraisal and the timelines remain to be confirmed.
As this appraisal has been referred, NICE will continue to monitor any developments and will provide an update as and when the situation changes.
| Status | Suspended |
| Decision | Selected |
| Process | STA 2018 |
| ID number | 1246 |
Project Team
| Project lead | Michelle Adhemar |
Email enquiries
- If you have any queries please email scopingta@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 08 July 2019 | Suspended. As you will be aware, the Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of pembrolizumab for previously treated triple-negative breast cancer. However, following on from information received from the company regarding the recent results of the KEYNOTE-119 clinical trial to support this indication and that they did not meet the pre-specified primary endpoint, NICE has decided to suspend this appraisal and the timelines remain to be confirmed. As this appraisal has been referred, NICE will continue to monitor any developments and will provide an update as and when the situation changes. |
| 26 September 2018 | As you will be aware, the Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of pembrolizumab for previously treated oesophageal or gastro-oesophageal junction cancer. Please note that the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in mid-January 2019 |
| 26 September 2018 | As you will be aware, the Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of pembrolizumab for previously treated oesophageal or gastro-oesophageal junction cancer. Please note that the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in mid-January 2019 |
| 31 January 2018 - 28 February 2018 | Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators |
| 31 January 2018 | In progress. In progress |
For further information on our processes and methods, please see our CHTE processes and methods manual